Key Points
- Director Colin Walsh sold 105,807 Attovia Therapeutics shares at an average price of $21.28, generating proceeds of approximately $2.25 million.
- One day later, Walsh purchased 500,000 shares at $17.00 each, a transaction valued at $8.5 million, indicating substantial net insider buying over the two-day period.
- Attovia shares opened at $19.18 and were reported up 6.2%; meanwhile, BlackRock increased its position by 23.4% in the second quarter to 164,358 shares.
Attovia Therapeutics, Inc. (NASDAQ:ATTO - Get Free Report) Director Colin Walsh sold 105,807 shares of the firm's stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $21.28, for a total value of $2,251,572.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Colin Walsh also recently made the following trade(s):
- On Thursday, August 6th, Colin Walsh acquired 500,000 shares of Attovia Therapeutics stock. The stock was purchased at an average price of $17.00 per share, with a total value of $8,500,000.00.
Attovia Therapeutics Stock Up 6.2%
NASDAQ:ATTO opened at $19.18 on Friday. Attovia Therapeutics, Inc. has a 1-year low of $16.15 and a 1-year high of $22.79.
Institutional Investors Weigh In On Attovia Therapeutics
A hedge fund recently raised its position in Attovia Therapeutics stock. BlackRock Inc. lifted its holdings in Attovia Therapeutics, Inc. (NASDAQ:ATTO - Free Report) by 23.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 164,358 shares of the company's stock after purchasing an additional 31,189 shares during the period. BlackRock Inc.'s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent quarter.
Attovia Therapeutics Company Profile
(
Get Free Report)
Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company's research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.
Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
